MedTrace Logo

Assessment of LBR-101 In Chronic Migraine

NCT02021773 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 264

Last updated 2021-12-09

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to determine whether monthly subcutaneous administration of LBR-101 (fremanezumab) is safe and provides migraine prevention in patients with chronic migraine.

Conditions

  • Chronic Migraine

Interventions

DRUG

LBR-101 High Dose

Subcutaneously Administered LBR-101 Monthly x 3

DRUG

LBR-101 Low Dose

Subcutaneously Administered LBR-101 Monthly x 3

DRUG

Placebo

Subcutaneously Administered Placebo (Vehicle) Monthly x 3

Sponsors & Collaborators

  • Teva Branded Pharmaceutical Products R&D, Inc.

    lead INDUSTRY

Principal Investigators

  • Teva Medical Expert, MD · Teva Branded Pharmaceutical Products R&D, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2015-02-28
Completion
2015-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02021773 on ClinicalTrials.gov